Exact out-of-equilibrium central spin dynamics from integrability

We consider a Gaudin magnet (central spin model) with a time-dependent exchange couplings. We explicitly show that the Schr\"odinger equation is analytically solvable in terms of generalized hypergeometric functions for particular choices of the time dependence of the coupling constants. Our method establishes a new link between this system and the SU(2) Wess-Zumino-Witten model, and sheds new light on the implications of integrability in out-of-equilibrium quantum physics. As an application, a driven four-spin system is studied in detail

Road user charging and implications for transport policy: Findings from the CURACAO project

This paper reports on the outcomes of a European project, CURACAO, designed to support the implementation of urban road user charging (URUC) as a demand management tool in urban areas. The project did this through engagement with a User Group of cities interested in pursuing URUC to identify the barriers preventing them from doing so. The project reviewed the complete process of setting up a URUC scheme from the setting of objectives, through to scheme design, predicting impacts, achieving acceptability and the implementation process and presented its findings in a State of the Art Report and a Case Studies Report. The State of the Art Report provides evidence collated from research and practice to address a series of 14 themes identified by the User Group, including objectives; scheme design; technology; business systems; prediction; traffic, environmental, economic and equity impacts; appraisal; acceptability; transferability; implementation; and evaluation. The Case Study Report reviewed 16 proposed or implemented schemes in Europe, focusing on pricing objectives, scheme design, the implementation process and scheme results. On this basis, the CURACAO Consortium developed a list of policy recommendations aimed at cities and regional authorities, national governments, and the European Commission. The paper summarises the main findings of the State of the Art Report and the case studies. On this basis, it outlines the policy recommendations which were drawn, and identifies future research needs

SGLT2 Inhibitors and the Diabetic Kidney

Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may have the potential to exert nephroprotection not only through improving glycemic control but also through glucose-independent effects, such as blood pressure-lowering and direct renal effects. It is important to consider, however, that in patients with impaired renal function, given their mode of action, SGLT2 inhibitors are less effective in lowering blood glucose. In patients with high cardiovascular risk, the SGLT2 inhibitor empagliflozin lowered the rate of cardiovascular events, especially cardiovascular death, and substantially reduced important renal outcomes. Such benefits on DN could derive from effects beyond glycemia. Glomerular hyperfiltration is a potential risk factor for DN. In addition to the activation of the renin-angiotensin-aldosterone system, renal tubular factors, including SGLT2, contribute to glomerular hyperfiltration in diabetes. SGLT2 inhibitors reduce sodium reabsorption in the proximal tubule, causing, through tubuloglomerular feedback, afferent arteriole vasoconstriction and reduction in hyperfiltration. Experimental studies showed that SGLT2 inhibitors reduced hyperfiltration and decreased inflammatory and fibrotic responses of proximal tubular cells. SGLT2 inhibitors reduced glomerular hyperfiltration in patients with type 1 diabetes, and in patients with type 2 diabetes, they caused transient acute reductions in glomerular filtration rate, followed by a progressive recovery and stabilization of renal function. Interestingly, recent studies consistently demonstrated a reduction in albuminuria. Although these data are promising, only dedicated renal outcome trials will clarify whether SGLT2 inhibitors, in addition to their glycemic and blood pressure benefits, may provide nephroprotective effects

Production of ber-based cavities by pressing heated balls into fiber tip

ope